Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000567001 | SCV000669870 | uncertain significance | Hereditary cancer-predisposing syndrome | 2017-07-06 | criteria provided, single submitter | clinical testing | The p.R106T variant (also known as c.317G>C), located in coding exon 2 of the MSH2 gene, results from a G to C substitution at nucleotide position 317. The arginine at codon 106 is replaced by threonine, an amino acid with similar properties. This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. In addition, this alteration is predicted to be benign by MAPP-MMR in silico analyses (Chao EC et al. Hum. Mutat. 2008 Jun;29:852-60). Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Color | RCV000567001 | SCV000905153 | likely benign | Hereditary cancer-predisposing syndrome | 2015-10-19 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000793779 | SCV000933151 | uncertain significance | Hereditary nonpolyposis colorectal neoplasms | 2018-12-05 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine with threonine at codon 106 of the MSH2 protein (p.Arg106Thr). The arginine residue is weakly conserved and there is a moderate physicochemical difference between arginine and threonine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with MSH2-related conditions. ClinVar contains an entry for this variant (Variation ID: 483749). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |